

Anti-CD11 Reference Antibody (Rovelizumab)

Recombinant Antibody Catalog # APR10475

Specification

Anti-CD11 Reference Antibody (Rovelizumab) - Product Information

Application FC, E, FTA
Primary Accession Q9UO88
Reactivity Human
Clonality Monoclonal
Isotype IgG4
Calculated MW 145.98 KDa

Anti-CD11 Reference Antibody (Rovelizumab) - Additional Information

Target/Specificity CD11

Endotoxin

< 0.001EU/ μg, determined by LAL method.

Conjugation Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Anti-CD11 Reference Antibody (Rovelizumab) - Protein Information

Name CDK11A

Synonyms CDC2L2, CDC2L3, PITSLREB

Function

Appears to play multiple roles in cell cycle progression, cytokinesis and apoptosis. The p110 isoforms have been suggested to be involved in pre-mRNA splicing, potentially by phosphorylating the splicing protein SFRS7. The p58 isoform may act as a negative regulator of normal cell cycle progression.

Cellular Location

Cytoplasm. Nucleus.

Tissue Location

Expressed ubiquitously. Some evidence of isoform- specific tissue distribution.




Anti-CD11 Reference Antibody (Rovelizumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

Anti-CD11 Reference Antibody (Rovelizumab) - Images



Anti-CD11 Reference Antibody (Rovelizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-CD11 Reference Antibody (Rovelizumab)is more than 99.22% ,determined by SEC-HPLC.